[Dementia and extrapyramidal problems caused by long-term valproic acid].
Identifieur interne : 001301 ( PubMed/Corpus ); précédent : 001300; suivant : 001302[Dementia and extrapyramidal problems caused by long-term valproic acid].
Auteurs : K. Masmoudi ; V. Gras-Champel ; I. Bonnet ; M. Pannier ; H. Masson ; A. Rosa ; M. AndréjakSource :
- Therapie [ 0040-5957 ]
English descriptors
- KwdEn :
- Aged, Anticonvulsants (adverse effects), Anticonvulsants (pharmacology), Anticonvulsants (therapeutic use), Basal Ganglia (metabolism), Basal Ganglia Diseases (chemically induced), Dementia (chemically induced), Female, GABA Agonists (adverse effects), GABA Agonists (pharmacology), GABA Agonists (therapeutic use), Humans, Male, Middle Aged, Parkinson Disease, Secondary (chemically induced), Valproic Acid (adverse effects), Valproic Acid (pharmacology), Valproic Acid (therapeutic use), gamma-Aminobutyric Acid (metabolism).
- MESH :
- chemical , adverse effects : Anticonvulsants, GABA Agonists, Valproic Acid.
- chemical , metabolism : gamma-Aminobutyric Acid.
- chemical , pharmacology : Anticonvulsants, GABA Agonists, Valproic Acid.
- chemical , therapeutic use : Anticonvulsants, GABA Agonists, Valproic Acid.
- chemically induced : Basal Ganglia Diseases, Dementia, Parkinson Disease, Secondary.
- metabolism : Basal Ganglia.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Among the side-effects attributed to valproic acid (VPA), the occurrence of Parkinsonian syndromes and cognitive impairment is very uncommonly reported. We describe five cases of reversible associated Parkinsonism. These cases were observed in epileptic patients, 57 to 74 years old, two women and three men. Extrapyramidal disorders appeared after various durations of treatment (from 6 months to 10 years). Dementia characterized by an insidious onset was associated in three cases and bradypsychia in one case. Brain pseudoatrophy was present in three patients. In all cases the signs and symptoms improved some weeks or months after discontinuation of VPA. In the literature some cases, usually in young adults or children, have been reported. In a prospective study, Armon et al. found various abnormal symptoms and signs related to motor and cognitive function impairment in patients with long-term VPA therapy. These side-effects may be related to a disturbance in the gabaergic pathways in the basal ganglia system. It is of interest to consider that delta 2-valproic acid, a metabolite of VPA, is especially accumulated in selected areas of the brain: the substantia nigra, superior and inferior colliculus, hippocampus and medulla.
PubMed: 11201978
Links to Exploration step
pubmed:11201978Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Dementia and extrapyramidal problems caused by long-term valproic acid].</title><author><name sortKey="Masmoudi, K" sort="Masmoudi, K" uniqKey="Masmoudi K" first="K" last="Masmoudi">K. Masmoudi</name><affiliation><nlm:affiliation>Service de Neurologie CHU Nord, 80054 Amiens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gras Champel, V" sort="Gras Champel, V" uniqKey="Gras Champel V" first="V" last="Gras-Champel">V. Gras-Champel</name></author><author><name sortKey="Bonnet, I" sort="Bonnet, I" uniqKey="Bonnet I" first="I" last="Bonnet">I. Bonnet</name></author><author><name sortKey="Pannier, M" sort="Pannier, M" uniqKey="Pannier M" first="M" last="Pannier">M. Pannier</name></author><author><name sortKey="Masson, H" sort="Masson, H" uniqKey="Masson H" first="H" last="Masson">H. Masson</name></author><author><name sortKey="Rosa, A" sort="Rosa, A" uniqKey="Rosa A" first="A" last="Rosa">A. Rosa</name></author><author><name sortKey="Andrejak, M" sort="Andrejak, M" uniqKey="Andrejak M" first="M" last="Andréjak">M. Andréjak</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2000 Sep-Oct</MedlineDate></PubDate></date><idno type="RBID">pubmed:11201978</idno><idno type="pmid">11201978</idno><idno type="wicri:Area/PubMed/Corpus">001301</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001301</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Dementia and extrapyramidal problems caused by long-term valproic acid].</title><author><name sortKey="Masmoudi, K" sort="Masmoudi, K" uniqKey="Masmoudi K" first="K" last="Masmoudi">K. Masmoudi</name><affiliation><nlm:affiliation>Service de Neurologie CHU Nord, 80054 Amiens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gras Champel, V" sort="Gras Champel, V" uniqKey="Gras Champel V" first="V" last="Gras-Champel">V. Gras-Champel</name></author><author><name sortKey="Bonnet, I" sort="Bonnet, I" uniqKey="Bonnet I" first="I" last="Bonnet">I. Bonnet</name></author><author><name sortKey="Pannier, M" sort="Pannier, M" uniqKey="Pannier M" first="M" last="Pannier">M. Pannier</name></author><author><name sortKey="Masson, H" sort="Masson, H" uniqKey="Masson H" first="H" last="Masson">H. Masson</name></author><author><name sortKey="Rosa, A" sort="Rosa, A" uniqKey="Rosa A" first="A" last="Rosa">A. Rosa</name></author><author><name sortKey="Andrejak, M" sort="Andrejak, M" uniqKey="Andrejak M" first="M" last="Andréjak">M. Andréjak</name></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anticonvulsants (adverse effects)</term><term>Anticonvulsants (pharmacology)</term><term>Anticonvulsants (therapeutic use)</term><term>Basal Ganglia (metabolism)</term><term>Basal Ganglia Diseases (chemically induced)</term><term>Dementia (chemically induced)</term><term>Female</term><term>GABA Agonists (adverse effects)</term><term>GABA Agonists (pharmacology)</term><term>GABA Agonists (therapeutic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Valproic Acid (adverse effects)</term><term>Valproic Acid (pharmacology)</term><term>Valproic Acid (therapeutic use)</term><term>gamma-Aminobutyric Acid (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term><term>GABA Agonists</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anticonvulsants</term><term>GABA Agonists</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>GABA Agonists</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Dementia</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Among the side-effects attributed to valproic acid (VPA), the occurrence of Parkinsonian syndromes and cognitive impairment is very uncommonly reported. We describe five cases of reversible associated Parkinsonism. These cases were observed in epileptic patients, 57 to 74 years old, two women and three men. Extrapyramidal disorders appeared after various durations of treatment (from 6 months to 10 years). Dementia characterized by an insidious onset was associated in three cases and bradypsychia in one case. Brain pseudoatrophy was present in three patients. In all cases the signs and symptoms improved some weeks or months after discontinuation of VPA. In the literature some cases, usually in young adults or children, have been reported. In a prospective study, Armon et al. found various abnormal symptoms and signs related to motor and cognitive function impairment in patients with long-term VPA therapy. These side-effects may be related to a disturbance in the gabaergic pathways in the basal ganglia system. It is of interest to consider that delta 2-valproic acid, a metabolite of VPA, is especially accumulated in selected areas of the brain: the substantia nigra, superior and inferior colliculus, hippocampus and medulla.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11201978</PMID><DateCreated><Year>2001</Year><Month>02</Month><Day>01</Day></DateCreated><DateCompleted><Year>2001</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>5</Issue><PubDate><MedlineDate>2000 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Dementia and extrapyramidal problems caused by long-term valproic acid].</ArticleTitle><Pagination><MedlinePgn>629-34</MedlinePgn></Pagination><Abstract><AbstractText>Among the side-effects attributed to valproic acid (VPA), the occurrence of Parkinsonian syndromes and cognitive impairment is very uncommonly reported. We describe five cases of reversible associated Parkinsonism. These cases were observed in epileptic patients, 57 to 74 years old, two women and three men. Extrapyramidal disorders appeared after various durations of treatment (from 6 months to 10 years). Dementia characterized by an insidious onset was associated in three cases and bradypsychia in one case. Brain pseudoatrophy was present in three patients. In all cases the signs and symptoms improved some weeks or months after discontinuation of VPA. In the literature some cases, usually in young adults or children, have been reported. In a prospective study, Armon et al. found various abnormal symptoms and signs related to motor and cognitive function impairment in patients with long-term VPA therapy. These side-effects may be related to a disturbance in the gabaergic pathways in the basal ganglia system. It is of interest to consider that delta 2-valproic acid, a metabolite of VPA, is especially accumulated in selected areas of the brain: the substantia nigra, superior and inferior colliculus, hippocampus and medulla.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masmoudi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Service de Neurologie CHU Nord, 80054 Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gras-Champel</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pannier</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Andréjak</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Démence et troubles extra-pyramidaux sous acide valproïque au long cours.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018755">GABA Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018755" MajorTopicYN="N">GABA Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11201978</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001301 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001301 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:11201978
|texte= [Dementia and extrapyramidal problems caused by long-term valproic acid].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11201978" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |